{
    "pmcid": "10578311",
    "qa_pairs": {
        "What are the conserved hot spots identified for targeting by broadly neutralizing nanobodies?": [
            "L455, F456, F486, Y489, and T500",
            "A475, G476, S477, T478, and E484",
            "N439, Y453, L452, K417, and E484",
            "P681, T716, S982, D614, and N679"
        ],
        "What is emphasized as necessary for maintaining the efficacy of nanobodies against emerging variants?": [
            "Continuous structural and functional characterization of new variants",
            "Increasing the dosage of existing nanobodies",
            "Developing new delivery methods for nanobodies",
            "Focusing solely on the wild-type RBD for nanobody design"
        ],
        "What is the primary target for therapeutic interventions in SARS-CoV-2 according to the paper?": [
            "The receptor-binding domain (RBD) of the spike protein",
            "The nucleocapsid protein",
            "The membrane protein",
            "The envelope protein"
        ],
        "What type of simulations provide structural insights for nanobody engineering?": [
            "Molecular dynamics simulations and free energy calculations",
            "Quantum mechanics simulations and density functional theory",
            "Monte Carlo simulations and lattice Boltzmann methods",
            "Finite element analysis and computational fluid dynamics"
        ],
        "Which mutations in the RBD are highlighted as affecting nanobody binding?": [
            "K417N, E484K/A, Q498R, N501Y, and Y505H",
            "D614G, P681R, L452R, T478K, and N679K",
            "A222V, S477N, T716I, V1176F, and D950N",
            "H69/V70 deletion, Y144 deletion, N439K, and S982A"
        ]
    }
}